BioSpace News Archive

iCAD’s cancer detection and therapy technologies to be exhibited together for the first time in the Middle East, including the world’s first commercial deep-learning digital breast tomosynthesis solution and a single-fraction therapy option for early-stage breast cancer

InMode Ltd. (Nasdaq: INMD) (“InMode”), a leading global provider of innovative medical technologies, introduces Evoke, a breakthrough non-invasive solution for facial remodeling.

InnerScope continues to launch its premium Hearing Health Products on Waltmart.com with Ear-Ring Relief™ Doctor-Designed & Formulated Dietary Supplement designed to reduce Ringing, Hissing and Buzzing Noises in the Ears for the 60 million Americans that suffer from Tinnitus

Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company engaged in commercializing novel pharmaceutical therapies, today announced that it has received notice from The Nasdaq Stock Market LLC (“Nasdaq”) that the Company has regained compliance with Nasdaq’s minimum bid price for continued listing on the Nasdaq Capital Market set forth in Nasdaq Listing Rule 5550(a)(2) (“Bid Price Rule”).

Lantheus Holdings, Inc., parent company of Lantheus Medical Imaging, Inc., a leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products, announced the appointment of Paul Blanchfield as Chief Commercial Officer, effective January 27, 2020.

Castellum, Inc. (OTC: ONOV) announces Jim Enicks, Colonel, U.S. Army Retired, has agreed to become CEO of the Company’s subsidiary, Corvus Consulting.

Eight Cochlear recipients recognized for their achievements in academia, leadership and humanity with $64,000 in funding for further academic endeavors

Natera, Inc. (NASDAQ: NTRA) a global leader in cell-free DNA testing, filed suit today against ArcherDX for infringement of Natera’s U.S. Patent No. 10,538,814 (the “‘814 patent”).

Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat autoimmune and inflammatory diseases where the complement and/or leukotriene systems are implicated, announces new preclinical data indicating that nomacopan significantly reduced both retinal inflammation and intraocular VEGF.

Enteris BioPharma, Inc., a biotechnology company developing innovative drug products built around its proprietary delivery technologies and a wholly-owned subsidiary of SWK Holdings Corporation (Nasdaq: SWKH), announced that it has received the 2019 Best of Boonton Award in the Pharmaceutical Company category from the Boonton Award Program.